GET DAILY SIGNALSInnovAge (INNV) Posts +12% Revenue Growth in Fiscal Q1 2027
Key Takeaways
- InnovAge reported fiscal first quarter 2027 revenue of approximately $264.8 million, up roughly 12% from $236.1 million a year earlier and ahead of analyst expectations.
- Diluted earnings per share (EPS) came in at $0.14, comfortably above the consensus estimate of about $0.08.
- Net income attributable to InnovAge Holding Corp. rose to roughly $19.6 million, compared with $8.0 million in the prior-year quarter.
- Management reaffirmed its full fiscal 2027 revenue guidance range of $1.05 billion to $1.085 billion.
- Growth continues to be driven by higher participant census and member months across the company's PACE (Program of All-Inclusive Care for the Elderly) network.
Earnings Context and Why It Matters
InnovAge Holding Corp. is a leading provider of care for high-cost, frail, predominantly dual-eligible seniors — those eligible for both Medicare and Medicaid — through the Program of All-Inclusive Care for the Elderly (PACE). The company's fiscal first quarter ended September 30, 2026, marks the opening chapter of what management calls "InnovAge 3.0," a shift from turnaround toward sustained growth after a fiscal 2026 in which adjusted EBITDA surged roughly 175%. With reimbursement-rate tailwinds expected to moderate, I am watching closely whether census growth and center-level margins can keep profitability climbing on the strength of execution alone.
Reported Results
For its fiscal first quarter of 2027, INNV reported total revenue of approximately $264.8 million, up about 12% from $236.1 million in the same period a year ago and above the consensus estimate of roughly $257 million. Diluted EPS reached $0.14, beating the analyst consensus of about $0.08 by a wide margin and improving sharply from $0.06 a year earlier.
Net income attributable to InnovAge Holding Corp. climbed to roughly $19.6 million from $8.0 million in the prior-year quarter, reflecting both higher member months and improved operating leverage. Management also reaffirmed its full-year fiscal 2027 revenue outlook of $1.05 billion to $1.085 billion, signaling confidence in continued top-line expansion even as rate increases normalize. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Shares of INNV entered the report under pressure, having pulled back from their recent highs as investors weighed a more moderate reimbursement-rate environment and state-level rate negotiations in key markets such as California and Colorado. Against that backdrop, a top-and-bottom-line beat — and particularly the wide EPS outperformance — offered a reassuring signal on execution, and the stock was modestly higher in after-hours trading following the announcement. Sentiment remains centered on whether profitability gains can be sustained through organic census growth rather than relying on the rate tailwinds that supported fiscal 2026.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will be watching whether InnovAge can convert its reaffirmed revenue guidance into continued margin expansion. Management has guided fiscal 2027 revenue to $1.05 billion to $1.085 billion, with census growth expected in the mid-single-digit to high-single-digit range as the company works toward roughly 8,625 to 8,850 participants by year-end.
Reimbursement dynamics remain a central variable. Medicare net rate increases are projected at only 1.5% to 2%, Medicaid increases are expected in the low single digits, and the transition to the V28 risk-adjustment model moves to a 50/50 blend in January 2027. Because California and Colorado together account for a large share of census, the pace of state rate finalization will be an important swing factor.
On the cost side, center-level contribution margin and external provider costs per participant will indicate whether operational discipline is holding as enrollment grows. Any update on de novo center losses, expansion opportunities, and technology investments will also help clarify the path toward the company's longer-term double-digit adjusted EBITDA margin target. As always, these observations are grounded in reported data and company guidance rather than price forecasts or investment recommendations. From what I see, the AI Trend Prediction Engine offers another useful lens on these trends.
Tickeron AI Tools for Research
I’ve found Tickeron’s AI Screener to be a practical addition to my workflow when evaluating names like INNV. It lets me quickly filter for technical patterns, fundamentals, and performance metrics across thousands of stocks, helping surface comparable ideas without manual effort. The tool integrates well with broader watchlist reviews and can highlight breakout candidates or volatility signals that complement traditional analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
INNV in downward trend: price may decline as a result of having broken its higher Bollinger Band on October 22, 2026
INNV broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 38 similar instances where the stock broke above the upper band. In 33 of the 38 cases the stock fell afterwards. This puts the odds of success at 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 52 cases where INNV's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INNV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where INNV's RSI Oscillator exited the oversold zone, 18 of 21 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on INNV as a result. In 100 of 112 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
The Moving Average Convergence Divergence (MACD) for INNV just turned positive on October 09, 2026. Looking at past instances where INNV's MACD turned positive, the stock continued to rise in 42 of 49 cases over the following month. The odds of a continued upward trend are 86%.
Following a +4.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where INNV advanced for three days, in 234 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 145 of 176 cases where INNV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.126) is normal, around the industry mean (204.027). INNV's P/E Ratio (-442.500) is considerably lower than the industry average of (19.383). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.092) among similar stocks. P/S Ratio (1.488) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. INNV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 78 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INNV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement